Antibodies against cell surface antigens as very potent immunological adjuvants

Vaccine

Volumn 24, Issue SUPPL. 2, 2006, Pages S20-

  Barr, Tom ^a   Carlring, Jennifer ^a   Hatzifoti, Caterina ^a   Heath, Andrew W ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adjuvant; Costimulation

Indexed keywords

ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOKINE; IMMUNOLOGICAL ADJUVANT; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY CD28;

ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; EXPERIMENTAL MODEL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; PRIORITY JOURNAL; VACCINATION;

EID: 33645240780     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.105     Document Type: Article

References (5)

1. T.A. Barr, P.L. Laing, and A.W. Heath Understanding and rational design of immunological adjuvants Innovations Pharm Technol 3 2003 71 79
2. P. Dullforce, D. Sutton, and A.W. Heath Enhancement of T independent immune responses in vivo by CD40 antibodies Nat Med 4 1998 88 91
3. T.A. Barr, A.L. McCormick, J. Carlring, and A.W. Heath A potent adjuvant effect of CD40 antibody attached to antigen Immunology 109 2003 87 91
4. J. Carlring, T. Barr, A.M. Buckle, and A.W. Heath Anti-CD28 has a potent adjuvant effect on the antibody response to soluble antigens mediated through CTLA4 by-pass Eur J Immunol 33 2003 135 142
5. Carlring J, Barr T, McCormick AL, Heath AW. CD40 antibody as an adjuvant induces enhanced T cell responses. Vaccine 2004;22:3323-8.